We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.75 | 1.73% | 44.00 | 43.00 | 45.00 | 44.00 | 43.25 | 43.25 | 151,709 | 08:19:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 23.25M | -24.95M | -0.0695 | -6.22 | 155.29M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/10/2024 08:38 | Yes, tell me then, when is the Phase II trial going to start? In September 2023 they said Phase II would be in 2024, they haven't even started Phase 1b yet. They have no approval to proceed to Phase II as far as I am aware nor the funds to do so. | 1347 | |
21/10/2024 08:21 | Excuse me? AV6k "quietly dropped"?Are we living in the same planet? | divmad | |
21/10/2024 07:45 | Yes that's about it and again it tends to indicate that their previous pipeline of AVA6000 and AVA3996 have been quietly dropped, along with all their other pre-clinical pipeline candidates, AVA004, AVA021, AVA027, AVA028, AVA032 as they don’t get a mention any longer. Now they have jumped on the AI bandwagon and they have yet another collaboration, pretty much all the previous ones having gone nowhere. I maintain my view that this is a jam tomorrow company that have achieved little and are very unlikely to for a long, long time, if ever. | 1347 | |
18/10/2024 19:44 | You seem very well researched Jaknife, I mean having all those company names to hand and in alphabetical order too...very impressive. The first time I've seen someone come out in support of TW on this thread. | cheshire pete | |
18/10/2024 18:22 | What's your price target here ? | nico115 | |
18/10/2024 12:52 | Quazie ...another newbie tool pops in for a punt. Peeps sold off at resistance as anticipated. Shame. Hope everyone has a decent weekend. PE Conf in NY next week. Dull as dishwater. Need to rest up before the fakery begins. Save me matron, save me! Groan. | amanitaangelicus | |
18/10/2024 09:11 | TW is a discredited numpty. Has banged on for years about others but his own track record...... hmmmmm | quazie12 | |
18/10/2024 07:42 | Shorties at it again??? | baldrick1 | |
18/10/2024 06:24 | Ah yes the Black Death, those were the days. Weren't ye olde Avacta doing some pre-clinical work then for a submission to the apothecary to hold a Phase I trial? Didn't they say they had a game changing treatment for it? | 1347 | |
17/10/2024 16:54 | Also, looking at the graph, resistance was clearly expected at these levels. Needs to break out now from here, or I fear that big downward channel will be well n truly confirmed. Needs to zoom,NOW! | amanitaangelicus | |
17/10/2024 16:52 | TW red flagging this again! I guess that.s where Whitey got his angst from as he can't think for himself. TW isn't v keen on AVA6k results - mmm. | amanitaangelicus | |
17/10/2024 16:50 | 1347 was the year Black Death came to Europe. Twenty million people died over the next five years ! Interesting fact don’t you think ! | fieldhouse | |
17/10/2024 15:42 | Closer but try again. | 1347 | |
17/10/2024 15:17 | After I have sold out today ;)))Until next buy in price. Good profits went into charity accounts. | baldrick1 | |
17/10/2024 15:00 | English not your first, or second, language then, or did you just not pay attention at school? It's incoherent, try again. | 1347 | |
17/10/2024 13:41 | 1347, Your altruism is only exceed by your egocentricity As I said a clever—— | fieldhouse | |
17/10/2024 13:18 | Only 8 more to drug updates to come | blackvulture | |
17/10/2024 12:50 | Anyone thinking it all seems strangely familiar will, of course, be entirely right, e.g. 5 years ago. | 1347 | |
17/10/2024 12:42 | More to come CC says We are thrilled to announce our two new additions to the Avacta pipeline. Our pre|CISION peptide drug conjugate technology can be implemented in multiple options. More to come soon. Stay tuned | pareden | |
17/10/2024 12:37 | When next placing RNS? | blackhorse23 | |
17/10/2024 10:22 | Whitey still on his crack pipe? He s persistent! Like Donald Trump with a pornstar. Best ignored. Silly child. Mind you, I did warn of fluff ends...this is another one. Years off generating money unless the SVA6k has been sooo successful, loadsa companies are queuing up for new farm in deals. We.ll see I guess. Amazing mkt cap again. Well done all holders who have such resolute faith. Wonder what the absent Smith thinks about his bairn producing the latest AVA.s for the least looked at C.s my the money focussed mkt/ big pharmas. Gonna be a fun, long journey. Ps told you the traders like Whitey will return ...they.re back. Fill that Crack pipe child! | amanitaangelicus | |
17/10/2024 09:43 | 1347 - "PWhite - stop splitting hairs, if a drug cannot get past Phase 1 it's a failure," Sorry its not splitting hairs for the drug used has got past Phase 1 and has been highly commercial since the mid 1970s. AVA6000 is a prodrug and like all the other AVAs is essentially a delivery system not a new drug. It is this delivery system that has failed not any particular drug. Avacta has now introduced a new cancer drug Exatecan. The issue that plagued AVA6000 still remains. They cannot prove at the pharmacological level how preCISION delivers the drug in a warhead to the tumour without toxicity elsewhere such as the heart. | pwhite73 | |
17/10/2024 08:58 | jacktrax - I sympathise with your position but actually if you think about it Avacta have not produced anything that will help you, even after the longest Phase 1 I've ever known. It would be great if they had, but they didn't. | 1347 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions